Protalix BioTherapeutics presented new data at ACR 2026 showing that PRX-115, a PEGylated uricase for uncontrolled gout, maintains lowered plasma uric acid levels for up to 85 days after a single dose. This supports the potential for less frequent dosing, which could reduce treatment burden and improve adherence. The ongoing Phase 2 RELEASE study is testing dosing intervals of 4 to 8 weeks, with top-line results expected in the second half of 2027. PRX-115 aims to address unmet needs in gout treatment by offering prolonged activity and reduced immunogenicity compared to current therapies.
The story about PRX-115 and its prolonged effect on plasma uric acid levels is presented here with relevant market data. For readers following the health sector, 100 of 150 priced US health stocks on Pluang rose while 26 fell. Eli Lilly And Co (LLY) rose 2.44% to USD 1,387.00 with a typical hold time of 94 days, Maravai LifeSciences Holdings Inc. Class A (MRVI) fell 2.26% to USD 7.35 with a typical hold time of 15 days, and InMode Ltd (INMD) rose 2.18% to USD 13.62 with a typical hold time of 34 days, as of Nov 09, 2026 17:41 WIB.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
